Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans

Drug Metabolism and Disposition

Volumn 34, Issue 6, 2006, Pages 961-970

  Wait, Jill C M ^a,b   Vaccharajani, Nimish ^a   Mitroka, James ^a   Jemal, Mohammed ^a   Khan, Sanaullah ^a   Bonacorsi, Samuel J ^a   Rinehart, J Kent ^a   Iyer, Ramaswamy A ^a,c  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b AMGEN INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CARBON 14; CARBONYL DERIVATIVE; DISULFIDE; DITHIOTHREITOL; DRUG METABOLITE; GEMOPATRILAT; PLASMA PROTEIN; THIOL GROUP; VASOPEPTIDASE INHIBITOR; AZEPINE DERIVATIVE; CARBON; PROTEINASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD LEVEL; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SYNTHESIS; FECES ANALYSIS; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHYLATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SPECIES COMPARISON; STEADY STATE; URINALYSIS; URINE LEVEL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; FECES; MALE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; URINE;

CANIS FAMILIARIS;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CARBON RADIOISOTOPES; DOGS; FECES; HUMANS; MALE; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33646798761     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007500     Document Type: Article

References (20)

1. Burnett JCJ (1999) Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 17 (Suppl 1):S37-S43.
2. Delaney NG, Barrish JC, Neubeck R, Natarajan S, Cohen M, Rovnyak GC, Huber G, Murugesan N, Girotra R, Sieber-McMaster E, et al. (1994) Mercaptoacyl dipeptides as dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Preliminary structure-activity studies. Bioorg Med Chem Lett 4:1783-1788.
3. Gilbert HF (1995) Thiol/disulfide exchange equilibria and disulfide bond stability. Meth Enzymol 251:8-28.
4. Hubner RA, Kubota E, Casley DJ, Johnston CI, and Burrell LM (2001) In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J Hypertens 19:941-946.
5. 2]omapatrilat after oral administration to rats, dogs and humans. Drug Metab Dispos 31:67-75.
6. 14C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans. Drug Metab Dispos 29:60-69.
7. Jemal M and Hawthorne DJ (1997a) Quantitative determination of BMS-186716, a thiol compound, in dog plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct. J Chromatogr Biomed Appl 693:109-116.
8. Jemal M and Hawthorne DJ (1997b) Quantitative determination of BMS-186716, a thiol compound, in rat plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases. J Chromatogr Biomed Appl 698:123-132.
9. Jemal M, Khan S, Teitz DS, McCafferty JA, and Hawthorne DJ (2001) LC/MS/MS determination of omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor and its sulfhydryl- and thioether-containing metabolites in human plasma. Anal Chem 73:5450-5456.
10. Keire DA, Mariappan SV, Peng J, and Rabenstein DL (1993) Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin. Biochem Pharmacol 46:1059-1069.
11. Klaassen CD, Eaton DL, and Cagen SZ (1981) Hepatobiliary disposition of xenobiotics, in Progress in Drug Metabolism (Bridges JW and Chasseaud LF eds) pp 1-75, John Wiley & Sons Ltd, New York.
12. Kripalani KJ, Dean AV, and Migdalof BH (1983) Metabolism of captopril-L-cysteine, a captopril metabolite, in rats and dogs. Xenobiotica 13:701-705.
13. Malhotra BK, Iyer RA, Soucek KM, Behr D, Liao WC, Mitroka J, Kaul S, Cohen MB, and Knupp CA (2001) Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects. J Clin Pharmacol 41:833-841.
14. Migdalof BH, Antonaccio MJ, McKinstry DN, Singhvi SM, Lan S-J, Egli P, and Kripalani K (1984) Captopril: pharmacology, metabolism and disposition. Drug Metab Rev 15:841-869.
15. Robl JA, Sulsky R, Sieber-McMaster E, Ryono DE, Cimarusti MP, Simpkins LM, Karanewsky DS, Chao S, Asaad MM, Seymour AA, et al. (1999) Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides. J Med Chem 42:305-311.
16. Sagnella GA (2002) Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst 3:90-95.
17. Seymour AA, Abboa-Offei BE, Smith PL, Mathers PD, Asaad MM, and Rogers WL (1995) Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 22:63-69.
18. Singh J, Kronenthal DR, Schwinden M, Godfrey JD, Fox R, Vawter EJ, Zhang B, Kissick TP, Patel B, Mneimne O, et al. (2003) Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921. Org Lett 5:3155-3158.
19. Trippodo NC, Panchal BC, and Fox M (1995) Repression of angiotensin II and potential of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 272:619-627.
20. Yang D, Li B, Ng F, Yan Y, Qu J, and Wu Y (2001) Synthesis and characterization of chiral N-O turns induced by α-aminoxy acids. J Org Chem 66:7303-7312.